MedeliX
Start asking

aztreonam

Cayston · ATC code J01DF01

Key facts
Active substance
aztreonam
Drug class
Monobactam antibiotic
ATC code
J01DF01
Authorisation
centrally authorised across the EU (EMA)
Dosage forms
Cayston 75 mg powder and solvent for nebuliser solution.
Marketing authorisation holder
Gilead Sciences Ireland UC
Information as of
2026-10-27

Key facts

Aztreonam is a monobactam antibiotic. As a nebuliser solution (Cayston) it is used for suppressive therapy of chronic Pseudomonas aeruginosa lung infections in cystic fibrosis.

What it is used for

  • Suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis aged 6 years and older

Dosing

  • Adults and children 6 years and older: 75 mg three times per 24 hours for 28 days, doses at least 4 hours apart
  • May be used in repeated cycles of 28 days on therapy followed by 28 days off
  • Use a bronchodilator before each dose; order: bronchodilator, mucolytics, then Cayston
  • Use only with the Altera nebuliser system
  • No dose adjustment in renal or hepatic impairment; caution when serum creatinine is markedly raised

Contraindications

  • Hypersensitivity to the active substance or any excipient

Important warnings

  • Allergic reactions: stop administration if they occur; rash may indicate allergy
  • Caution in patients with a history of beta-lactam allergy (cross-reactivity possible, risk low)
  • Bronchospasm has been reported after administration
  • Haemoptysis

Side effects

  • Very common: cough (58%), nasal congestion (18%), wheezing (15%), pharyngolaryngeal pain (13.0%), pyrexia (12%), dyspnoea (10%)
  • Common: bronchospasm, chest discomfort, rhinorrhoea, haemoptysis, rash, arthralgia, decreased lung function
  • Uncommon: joint swelling

Interactions

  • No interaction studies; no evidence of interactions in studies with bronchodilators, dornase alfa, pancreatic enzymes, azithromycin, tobramycin and steroids

Pregnancy and breastfeeding

  • No data in pregnant women; should not be used in pregnancy unless the woman's clinical condition requires treatment with aztreonam

Summary of the official product information, written with AI (Claude, Anthropic) on 2026-10-28. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

Package leaflet for patients →

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

  • CaystonGilead Sciences Ireland UC · EMEA/H/C/000996

Source: European Medicines Agency (EMA), product information

Austria

  • AzactamLaboratoires Delbert · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-28

Brand names in 12 more European countries
Belgium
Azactam
Finland
Azactam
France
Azactam
Iceland
Cayston
Ireland
Azactam
Liechtenstein
Cayston
Luxembourg
Azactam
Norway
Azactam, Cayston
Portugal
Azactam
Romania
Azactam
Spain
Azactam
Sweden
Azactam

EMA – Article 57 product data (EU/EEA), 2026-10-28

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Related calculators

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. European Medicines Agency. Cayston – EPAR, Product Information (OF THE TEXT Detailed information on this medicinal product i). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/cayston-epar-product-information_en.pdf
  2. EMA – Article 57 product data (EU/EEA), 2026-10-28. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  3. Wikidata (CC0): ATC J01DF.

Editorial: Medelix editorial team · last updated 2026-10-27 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.